Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial

Psoriatic arthritis (PsA) is often poorly responsive to 2nd line antirheumatic drug therapy. Sulfasalazine has recently gained wide acceptance in the treatment of rheumatoid arthritis, and beneficial effects have also been noted in ankylosing spondylitis and reactive arthritis. We report a double bl...

Full description

Saved in:
Bibliographic Details
Published inJournal of rheumatology Vol. 22; no. 5; p. 894
Main Authors Gupta, A K, Grober, J S, Hamilton, T A, Ellis, C N, Siegel, M T, Voorhees, J J, McCune, W J
Format Journal Article
LanguageEnglish
Published Canada 01.05.1995
Subjects
Activities of Daily Living
Antirheumatic Agents - therapeutic use
Arthritis, Psoriatic - drug therapy
Blood Sedimentation
Double-Blind Method
Female
Humans
Male
Middle Aged
Placebos
Serum Globulins
Sulfasalazine - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Psoriatic arthritis (PsA) is often poorly responsive to 2nd line antirheumatic drug therapy. Sulfasalazine has recently gained wide acceptance in the treatment of rheumatoid arthritis, and beneficial effects have also been noted in ankylosing spondylitis and reactive arthritis. We report a double blind placebo controlled study of sulfasalazine in PsA. Twenty-four patients with active PsA were randomized to receive either sulfasalazine (3 g/day) (n = 10) or placebo (n = 14) for 8 weeks, in a double blind manner, followed by an 8 week open label crossover phase for nonresponding placebo patients. Compared with placebo controls, sulfasalazine treated patients were significantly improved at Weeks 4 and 8 with respect to physician (p < 0.01) and patient (p < 0.05) global assessments. Duration of morning stiffness was significantly decreased at Week 8 (p < 0.01). Clinical variables of disease activity returned to baseline after a 4 week drug washout period in 5 evaluable patients. Six patients in the placebo group crossed over to an 8 week open label phase and demonstrated significant improvements in joint scores, 50 ft walking time, and global patient assessment. Sulfasalazine treated patients also showed significant improvements in cutaneous involvement. Sulfasalazine was effective in PsA, with efficacy observed as early as the 4th week of treatment. Longterm studies are needed to determine whether such therapy can modify disease outcome.
ISSN:0315-162X